"Kyverna has entered 2025 and its next phase of growth with the right strategy and a strong team in place to advance late-stage development of KYV-101 in our three priority indications – stiff ...

The first catalyst of which is a meeting with regulators to confirm that there is an Accelerated Pathway forward in using its CD-19 CAR-T KYV-101 for these patients. Such a meeting is expected to ...

This year, Kyverna Therapeutics is anticipating several key milestones for its investigational CAR T therapy KYV-101. Like BMS, Kyverna’s approach targets CD19 to eliminate dysfunctional immune cells, ...